Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint-Reference-Cited by-同舟云学术

Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint

Published:2016-10-17 Issue:12 Volume:21 Page:1490-1495
ISSN:1360-2276
Container-title:Tropical Medicine & International Health
language:en
Short-container-title:Trop Med Int Health

Author:

Ravinetto Raffaella¹²,De Weggheleire Anja¹,Dorlo Thomas P.C.³⁴,Francque Sven⁵,Sokkab An⁶,Pouget Corinne⁷,Meessen Bruno⁸,Tabernero Patricia⁹,Newton Paul N.¹⁰¹¹¹²¹³,Lynen Lut¹

Affiliation:

1. Clinical Sciences Department Institute of Tropical Medicine Antwerp Belgium

2. Clinical Pharmacology and Pharmacotherapy KU Leuven Leuven Belgium

3. Department Pharmaceutical Biosciences Uppsala University Uppsala Sweden

4. Division of Pharmacoepidemiology & Clinical Pharmacology Utrecht University Utrecht The Netherlands

5. University of Antwerp Antwerp Belgium

6. Sihanouk Hospital Centre of Hope Phnom Penh Cambodia

7. QUAMED Institute of Tropical Medicine Antwerp Belgium

8. Public Health Department Institute of Tropical Medicine Antwerp Belgium

9. INSERM U 1058 Montpellier France

10. Lao‐Oxford‐Mahosot Hospital‐Wellcome Trust Research Unit Mahosot Hospital Vientiane Lao PDR

11. Centre for Tropical Medicine & Global Health Nuffield Department of Medicine Oxford University Oxford UK

12. Worldwide Antimalarial Resistance Network Churchill Hospital Oxford University Oxford UK

13. London School of Hygiene and Tropical Medicine London UK

Funder

Wellcome Trust

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Parasitology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tmi.12784

Reference48 articles.

1. Global epidemiology and genotype distribution of the hepatitis C virus infection

2. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment

3. Interferon-free combination therapies for the treatment of hepatitis C: current insights

4. Hepatitis C: cost of lost opportunities

5. Hepatitis C drug affordability

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intraspecies differences in natural susceptibility to amphotericine B of clinical isolates of Leishmania subgenus Viannia;PLOS ONE;2018-04-26

2. Generics for the Treatment of Hepatitis C in Monoinfected And HIV-Coinfected Patients: Pros and Cons;Aids Reviews;2017-09-30

3. Generic Direct Acting Antiviral Treatment: The First Step Towards Elimination of Hepatitis C in Iran;Hepatitis Monthly;2017-01-22